Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Cash flow from operating activities
Net income (loss)	$ 75,935	$ (22,782)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Stock-based compensation expense	8,108	6,998
Depreciation	3,106	5,357
Amortization of premiums and discounts on marketable securities	(1,832)	(23)
Loss on disposal of fixed assets	143
Other non-cash items		(2,468)
Changes in operating assets and liabilities:
Accounts receivable		(10,000)
Related party collaboration receivable	(2,996)	507
Prepaid expenses and other current assets	(342)	(1,652)
Operating lease, right-of-use asset	1,459	3,005
Accounts payable	704	763
Accrued expenses	3,236	1,536
Operating lease liabilities	(2,102)	(3,280)
Other non-current liabilities		(151)
Deferred revenue	16,260	21,925
Net cash provided by (used in) operating activities	101,679	(265)
Cash flow from investing activities
Purchases of property and equipment	(2,501)	(1,558)
Purchases of marketable securities	(194,975)	(54,848)
Proceeds from sales and maturities of marketable securities	29,000	35,000
Net cash used in investing activities	(168,476)	(21,406)
Cash flow from financing activities
Proceeds from the exercise of stock options	1,829	602
Proceeds from the issuance of common stock in connection with the 2023 Neurocrine Collaboration Agreement	31,121
Proceeds from the purchase of common stock under ESPP	235	232
Net cash provided by financing activities	33,185	834
Net decrease in cash, cash equivalents, and restricted cash	(33,612)	(20,837)
Cash, cash equivalents, and restricted cash beginning of period	100,474	119,212
Cash, cash equivalents, and restricted cash end of period	$ 66,862	98,375
Supplemental disclosure of cash and non-cash activities
Capital expenditures incurred but not yet paid		$ 40